Middleby: Insiders Are Buying Like Something’s Cooking (and Not Just in the Kitchen…)
Insiders are grabbing shares of Middleby like fresh-baked cookies—$93M worth in May alone. With buybacks, spinoffs, and top-tier equipment across commercial, residential, and food processing, this stock may be more than a kitchen story. Is it time to take a bite?
Viatris: The CEO Just Bought Shares… Should You Pop a Pill or Press "Buy"?
When a CEO personally buys over half a million dollars of stock, it’s time to pay attention. Viatris (VTRS) may be undervalued, with insider confidence, institutional backing, and a promising drug pipeline. But big losses and high debt mean it’s not risk-free. Is now the time to nibble?
Repay Holdings: Time to Reward the Patient Holder?
Insider buying is heating up at Repay Holdings. With over 200 institutions on board and a bargain-bin valuation, this fintech underdog might be getting ready to repay patient investors—with upside.
UnitedHealth Group: What if the Health of Your Portfolio Demands It?
UnitedHealth Group just saw two key insiders drop over $30M into the stock. That’s not a small co-pay—it’s serious belief. The stock is down 50% from its highs, but with strong earnings, defensive sector status, and a new-old CEO at the helm, could this be the comeback your portfolio needs?
Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!
Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?
🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!
After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?
🏠 Douglas Elliman (DOUG): Luxury Real Estate, Budget Stock Price?
Insiders are buying big, the company’s cutting losses, and the cash pile is solid. Douglas Elliman might not be flashy, but it’s not flopping either. A low-priced luxury real estate play worth a look?
🧬 GeneDx (WGS): Profit, Progress, and a 43% Plunge? Sounds Genetic.
GeneDx is profitable. Revenues are growing. Innovation is real. So why did the stock tank 43%? Here’s your deep-dive into the DNA of a biotech rollercoaster—with humor, icons, and a whole lot of exome.
🧴 International Flavors & Fragrances Stinks... No Longer?
IFF just reported a billion-dollar loss and still sports high debt, but insiders are loading up and institutional giants aren't flinching. It may still stink… or maybe it’s just getting interesting.
🚛 Heartland Express: Back Up the Truck Before It’s Too Late!
Insiders are buying, the CEO owns 32 million shares, and the balance sheet's tightening up—even as losses persist. Is Heartland Express (HTLD) stuck in reverse or about to hit the gas?